Virus therapy takes on deadly brain cancer in early trial
NCT ID NCT07126990
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new oncolytic virus (Ad-TD-nsIL12) in 40 adults with high-grade glioma, a fast-growing brain tumor. The virus is designed to infect and kill cancer cells while boosting the immune system. The main goal is to see how many patients survive at least 12 months after treatment. Participants must have newly diagnosed tumors in certain brain areas and not have had prior anti-tumor therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sanbo Brain Hospital, Capital Medical University
Beijing, Chaoyang District, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can adding lenvatinib to standard care outsmart a tough brain cancer?
- Can a sharper beam of radiation shield the mind during brain tumor treatment?
- Can a tiny implant trap brain tumor cells and make radiation work better?
- Can a targeted pill slow brain tumor growth after surgery?
- Brain surgery gets a GPS: network maps may help remove tumors while preserving function